Answers are grounded in this paper and cite their sources.
Interleukin (IL)‐13 plays a central role in Type 2 inflammation, contributing to the pathogenesis of atopic dermatitis, asthma, and related inflammatory diseases. APG777 is a novel anti‐IL‐13 monoclonal antibody engineered for improved pharmacokinetics and reduced dosing frequency. This first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple subcutaneous doses of APG777 in healthy adults. Forty participants were enrolled in single ascending dose (300–1200 mg) and multiple dose (300 mg × 2) cohorts. APG777 was well tolerated, with only mild‐to‐moderate treatment‐emergent adverse events, predominantly unrelated to the study drug. No serious or severe drug‐related treatment‐emergent adverse events occurred. Following single doses, APG777 exhibited dose‐proportional increases in C max and area under the curve, with a terminal half‐life ranging from 75.3 to 77.5 days across the dose range tested. Immunogenicity was low, with anti‐drug antibodies detected in 23.3% of treated participants, generally without impact on pharmacokinetics or safety. APG777 led to rapid and durable inhibition of the IL‐13‐driven biomarkers phosphorylated signal transducer and activator of transcription 6 (pSTAT6), thymus and activation‐regulated chemokine (TARC), and immunoglobulin E (IgE), with near‐complete suppression of pSTAT6 observed for up to 12 months post‐dose. The safety and optimized pharmacokinetic profile of APG777 supports evaluation of extended dosing intervals (every 3–6 months) and higher exposures, which could improve outcomes and reduce injection burden in patients with Type 2 inflammatory diseases including atopic dermatitis and asthma.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: